Loading
The first prospective trial dedicated to plasma cell leukaemia showed that a bortezomib-based four-drug induction followed by stem cell transplantation could produce remissions in most patients, though relapse remained the rule.
Phase 2 study of 40 patients with primary plasma cell leukaemia treated with bortezomib, doxorubicin, cyclophosphamide and dexamethasone induction followed by autologous transplant and, for those with a donor, reduced-intensity allogeneic transplant, or a second autologous transplant and maintenance.
Response after induction was 69 percent, median progression-free survival 15.1 months and median overall survival 36.3 months, a clear improvement on historical series with median survival under a year.
Bortezomib-based induction with early transplant consolidation became the accepted approach for fit patients with this rare aggressive disease; daratumumab-containing quadruplets are now added by extrapolation.
Shares Bortezomib, Dexamethasone, Cyclophosphamide.
Shares Plasma cell leukaemia, Bortezomib.
Shares Bortezomib, Journal of Clinical Oncology.
Shares Bortezomib, Dexamethasone.
Shares Dexamethasone, Doxorubicin, Cyclophosphamide.
Shares Bortezomib, Dexamethasone, Cyclophosphamide.